[HTML][HTML] Approved HIV reverse transcriptase inhibitors in the past decade
G Li, Y Wang, E De Clercq - Acta Pharmaceutica Sinica B, 2022 - Elsevier
HIV reverse transcriptase (RT) inhibitors are the important components of highly active
antiretroviral therapies (HAARTs) for anti-HIV treatment and pre-exposure prophylaxis in …
antiretroviral therapies (HAARTs) for anti-HIV treatment and pre-exposure prophylaxis in …
Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment
Y Wang, E De Clercq, G Li - Expert opinion on drug metabolism & …, 2019 - Taylor & Francis
Introduction: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are essential
components of highly active antiretroviral therapy against HIV-1 infections. Here, we provide …
components of highly active antiretroviral therapy against HIV-1 infections. Here, we provide …
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal …
A Mocroft, JD Lundgren, M Ross, CA Fux, P Reiss… - The lancet HIV, 2016 - thelancet.com
Background Whether or not the association between some antiretrovirals used in HIV
infection and chronic kidney disease is cumulative is a controversial topic, especially in …
infection and chronic kidney disease is cumulative is a controversial topic, especially in …
Are new antiretroviral treatments increasing the risk of weight gain?
S Shah, L Hindley, A Hill - Drugs, 2021 - Springer
There is a growing body of evidence from both observational and randomised trials
implicating integrase inhibitors, particularly dolutegravir and bictegravir, with the …
implicating integrase inhibitors, particularly dolutegravir and bictegravir, with the …
Brief report: switching to DOR/3TC/TDF maintains HIV-1 virologic suppression through week 144 in the DRIVE-SHIFT trial
P Kumar, M Johnson, JM Molina… - JAIDS Journal of …, 2021 - journals.lww.com
Background: In the primary analysis of the DRIVE-SHIFT trial, switching to
doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintained suppression …
doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintained suppression …
Brief report: efficacy and safety of oral islatravir once daily in combination with doravirine through 96 weeks for treatment-naïve adults with HIV-1 infection receiving …
JM Molina, Y Yazdanpanah, AA Saud… - JAIDS Journal of …, 2022 - journals.lww.com
Background: Islatravir (MK-8591) is a nucleoside reverse transcriptase translocation
inhibitor in development for treatment and prevention of HIV-1. We present efficacy and …
inhibitor in development for treatment and prevention of HIV-1. We present efficacy and …
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b …
JM Molina, Y Yazdanpanah, AA Saud, C Bettacchi… - The Lancet …, 2021 - thelancet.com
Background Islatravir is a nucleoside reverse transcriptase translocation inhibitor in
development for the treatment and prevention of HIV-1 infection. We aimed to assess the …
development for the treatment and prevention of HIV-1 infection. We aimed to assess the …
Switch to fixed-dose doravirine (100 mg) with islatravir (0· 75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a …
JM Molina, G Rizzardini, C Orrell, A Afani, A Calmy… - The Lancet …, 2024 - thelancet.com
Background Doravirine and islatravir is an investigational, once-daily, single-tablet regimen
with high antiviral potency, favourable safety and tolerability, and low propensity for …
with high antiviral potency, favourable safety and tolerability, and low propensity for …
Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy: Republication
S Shah, A Hill - Current opinion in HIV and AIDS, 2021 - journals.lww.com
Longer term studies are required to understand the metabolic impact of INSTIs, secondary to
weight gain. Evidence suggests that INSTIs, when used with TAF, contribute to metabolic …
weight gain. Evidence suggests that INSTIs, when used with TAF, contribute to metabolic …
Hepatotoxicity of contemporary antiretroviral drugs: a review and evaluation of published clinical data
AO Otto, CG Rivera, JD Zeuli, Z Temesgen - Cells, 2021 - mdpi.com
Contemporary antiretroviral agents afford enhanced potency and safety for patients living
with HIV. Newer antiretroviral drugs are often better tolerated than those initially approved in …
with HIV. Newer antiretroviral drugs are often better tolerated than those initially approved in …